BioSpace News Archive

After a topsy-turvy 2023, thousands of industry stakeholders will attend next week’s J.P. Morgan Healthcare Conference in San Francisco to answer a fundamental question: What will this year look like?

Basilea Pharmaceutica Ltd reported on the progress within its R&D portfolio in 2023 and upcoming milestones and timelines.

Addex Therapeutics announced that Tim Dyer, Chief Executive Officer, will present at Biotech Showcase being held in San Francisco, January 8-10, 2024.

Vico Therapeutics B.V. announced a $60 million Series B financing.

Sensorion announces that the research partnership framework agreement signed in 2019 with the Institut Pasteur granting Sensorion an option for exclusive licenses to develop and market gene therapy drug candidates from collaborative projects to address unmet medical needs in the hearing field has been extended for a period of five years.

Swedish Orphan Biovitrum AB’s Chairman of the Board Bo Jesper Hansen resigns, at his own request and with immediate effect, from his position as Chairman of the Board and board member due to health reasons.

Sosei Group Corporation announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer.

SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for kidney diseases, announces its acquisition by Novartis, a global medicines company.

selectION, Inc. announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Bionomics Limited announced that it will be presenting at the Biotech Showcase™ 2024 taking place January 8-10 in San Francisco, California.